A study of evaluating the effect of oral intake of BARLEYmax on human skin condition. A randomized, double-blind, placebo-controlled trial.

A study of evaluating the effect of oral intake of BARLEYmax on human skin condition. A randomized, double-blind, placebo-controlled trial. - The study of BARLEYmax on human skin condition.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033937

Enrollment

1000

Registered

2021-04-01

Start date

2018-08-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Placebo, 12 g/d for 8 weeks BARLEYmax, 12 g/d for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1)Individuals aged more than 20 years old. (2)The subjects who agreed with the consent of MYCODE research.

Exclusion criteria

Exclusion criteria: (1)Individuals who are participating in other clinical trials. (2)Individuals who may develop allergic symptoms due to wheat.

Design outcomes

Primary

Measure	Time frame
Questionnaires regarding to skin condition	—

Secondary

Measure	Time frame
Questionnaires regarding to feces and systemic health Blood test(IgE, TARC, eosinophil) Gut microbiota Free description	—

Countries

Japan

Contacts

Public ContactTakashi Fujitomo

DeNA Life Science Inc. R&D Gr.

IRB_dls@dena.com03-4366-7219

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026